Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original empirical data
PubMed 26146622 · doi:10.1155/2015/549412
What was done
This is a narrative review examining the biological roles of hypoxia-inducible factor-1 (HIF-1) in physiological and pathophysiological angiogenesis, vasculogenesis, glucose metabolism, and cell proliferation. The authors evaluate interactions between HIF-1 and other proangiogenic mediators (such as VEGF, placental growth factor, and angiopoietins) and discuss potential clinical therapeutic strategies targeting the HIF-1 pathway in ischemic conditions and malignancies.
What was found
The abstract reports no quantitative data or specific numerical results. It describes qualitative mechanistic pathways, noting that HIF-1 acts as a primary transcriptional regulator under hypoxic stress and functions synergistically with proangiogenic factors like VEGF, PlGF, and angiopoietins to regulate vascular development.
Why it matters
Understanding HIF-1 signaling clarifies how tissue hypoxia drives vascular remodeling, providing a theoretical framework for drug development targeting pro-angiogenic therapy in ischemic disorders or anti-angiogenic strategies in cancer.
Limits
As a narrative review, it presents mechanism-based reasoning rather than new empirical clinical trial data. Search methodology, study inclusion criteria, and formal risk-of-bias evaluations are not reported. No quantitative effect sizes, clinical outcomes, or sample sizes are provided in the abstract.
Cited by
- supports Changes in blood oxygenation trigger hypoxia-inducible factor 1-alpha (HIF-1a), which enhances transcription of vascular endothelial growth factor (VEGF) to promote blood vessel growth.